Twitch Interactive, Inc. has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening IPR2026-00397 on June 29, 2026. As of the initial docket entry, the proceeding is identified under Twitch’s name, but practitioners will want to watch closely for the patent owner, challenged patent number, and petition details as the Board record develops. View full case on Docket Alarm.

Although the early case caption does not yet reveal the full set of underlying merits documents, an IPR filing by a platform like Twitch is immediately notable.

Twitch Interactive, Inc. has launched a new proceeding at the Patent Trial and Appeal Board, filing inter partes review petition IPR2026-00397 on June 29, 2026. For patent litigators and in-house IP teams, the case is worth watching both for what it may reveal about Twitch’s broader patent risk strategy and for how the Board approaches the prior art and validity issues raised in the petition.

At this early stage, the PTAB docket reflects the filing of the petition, but practitioners will want to monitor the record closely for the patent owner’s preliminary response, the Board’s institution decision, and any related district court litigation that may shape the parties’ positions.

A new inter partes review filed at the Patent Trial and Appeal Board could be one to watch for companies operating at the intersection of life sciences, nutraceuticals, and consumer health. In IPR2026-00400, the proceeding is captioned Thorne Research, Inc. and was filed on June 22, 2026.

At this early stage, the PTAB docket signals that a patent challenge involving Thorne Research is underway, but practitioners should note that key details—including the specific patent claims at issue, the identity of the petitioner and patent owner as reflected in the styled papers, and the precise invalidity combinations asserted—may develop as the record fills out.

A new inter partes review, IPR2026-00400, was filed on June 22, 2026, at the Patent Trial and Appeal Board against Thorne Research, Inc. The proceeding is one to watch for companies operating at the intersection of dietary supplements, formulations, and health-focused consumer products, where patent value often turns on how broadly claims are drafted and how well they withstand validity attacks based on published prior art.

At this stage, the publicly available docket information identifies Thorne Research, Inc. as the patent owner, but practitioners should review the petition and related filings to confirm the specific challenged patent, the real parties in interest, and the exact claims at issue as the record develops.

Tesla has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening IPR2026-00380 on June 18, 2026. At this early stage, the public docket identifies the proceeding under the caption Tesla Inc., but key details that practitioners will want to monitor—including the patent owner, the specific patent number, and the prior-art combinations asserted—may become clearer as the petition and related papers are added to the record.

Even with a limited docket snapshot, the filing itself is notable.

A new inter partes review, IPR2026-00376, was filed at the Patent Trial and Appeal Board on June 18, 2026, naming Luxottica of America Inc. in the proceeding. While the publicly available docket caption confirms the PTAB filing and the involvement of Luxottica, this is the kind of early-stage matter patent practitioners will want to watch closely as the petition, patent-at-issue, and asserted invalidity theories come into sharper focus.

At this stage, the key takeaway is that a petitioner has asked the PTAB to institute trial on one or more claims of a patent connected to Luxottica.

Tesla Inc. has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening IPR2026-00380 on June 18, 2026.

ResMed Corp. has been named in a new inter partes review, IPR2026-00341, filed on June 12, 2026, before the Patent Trial and Appeal Board. While the newly filed docket entry identifies the proceeding by the company name, practitioners will want to watch closely as the petition develops and the challenged patent, claims at issue, and prior-art combinations come into sharper focus through the institution briefing.

At this stage, the publicly available case caption signals that a patent associated with ResMed’s portfolio is being challenged at the PTAB.

Tesla Inc. is the named petitioner in a newly filed inter partes review, IPR2026-00382, at the Patent Trial and Appeal Board, adding another matter for practitioners tracking high-stakes validity disputes before the USPTO.

The Patent Trial and Appeal Board’s Final Written Decision in IPR2025-00230 is a useful reminder of how decisively the Board will resolve validity disputes when the petitioner’s prior-art combinations, expert support, and claim construction positions align cleanly with the intrinsic record. In this June 11, 2026 decision, the PTAB concluded the inter partes review on the merits and determined the patentability of the challenged claims under the instituted grounds.

Although each final written decision turns on the particular technology and references at issue, the structure of the Board’s analysis here follows a familiar and important pattern for practitioners.

A new inter partes review has been filed at the Patent Trial and Appeal Board against ResMed Corp., opening another front in the increasingly important fight over respiratory and sleep-therapy technology. The petition, docketed as IPR2026-00341 and filed June 12, 2026, places at issue the validity of a ResMed patent before the PTAB, where petitioners can seek cancellation of issued patent claims based on prior art patents and printed publications.

At this early stage, the publicly available docket information identifies the proceeding as Resmed Corp., but does not yet provide the full set of petition details typically most relevant to practitioners, including the patent number, the petitioner’s identity, and the specific prior-art combinations asserted.

Another PTAB proceeding has been filed against ResMed, with IPR2026-00341 entering the Patent Trial and Appeal Board on June 12, 2026. The petition places one of ResMed’s patents under inter partes review, opening a new front in what could become an important dispute for companies operating in the sleep-disorder and respiratory-device space.

At this stage, the publicly available docket identifies the proceeding by the title Resmed Corp., but practitioners will want to monitor the case record closely as the petition, mandatory notices, and related filings further clarify the specific patent claims at issue, the identity of all real parties in interest, and any parallel district court or ITC litigation that may shape the Board’s discretionary-review analysis.

As with any newly filed IPR, the key issues will center on which patent is being challenged, which claims are targeted, and what prior-art grounds are asserted. Typically, petitioners rely on anticipation and obviousness grounds under 35 U.S.C. §§ 102 and 103, supported by combinations of patents, printed publications, and expert declarations.

A new inter partes review proceeding at the Patent Trial and Appeal Board could draw close attention from patent owners, challengers, and counsel following the medical technology sector. In IPR2026-00341, filed June 12, 2026, the petition is styled Resmed Corp., signaling that ResMed is involved in a fresh PTAB dispute over the validity of an issued patent.

At this early stage, the public docket identifies the proceeding but may not yet fully reflect all underlying petition details, including the specific patent number, all real parties in interest, and the complete list of asserted prior-art grounds.

A new inter partes review, IPR2026-00391, was filed on June 5, 2026, at the Patent Trial and Appeal Board naming Teladoc Health, Inc. in the proceeding. The filing places another spotlight on the digital health and telemedicine patent landscape, where platform functionality, remote care workflows, and software-driven healthcare delivery continue to generate high-stakes validity disputes.

At this early stage, the PTAB docket identifies the proceeding by title but may not yet reflect the full set of publicly available petition details practitioners typically watch for, including the specific patent number, the complete alignment of petitioner and patent owner, and the precise prior-art combinations asserted in the challenge.

A new inter partes review, IPR2026-00387, was filed at the Patent Trial and Appeal Board on June 5, 2026, under the caption Optiver US LLC. At this early stage, the proceeding is notable less for a developed merits record and more for what it signals: another PTAB dispute involving a sophisticated market participant, with the potential to touch on commercially important technology and high-stakes parallel enforcement or licensing issues.

Based on the docket currently available, the proceeding names Optiver US LLC as the petitioner.